首页|泛免疫炎症指数在肿瘤预后疗效的研究进展

泛免疫炎症指数在肿瘤预后疗效的研究进展

扫码查看
泛免疫炎症指数(PIV)是一种基于全血细胞计数的综合性免疫炎症生物标志物,已被证实能够预测不同肿瘤类型的治疗反应和生存结局.然而,PIV在不同肿瘤治疗策略中的预测价值存在差异.本研究旨在系统综述PIV预测免疫治疗、放射治疗、靶向治疗、内分泌治疗、手术治疗以及新辅助治疗等不同肿瘤治疗方式的生存效果指标和肿瘤预后的最新进展,分析其存在的挑战和问题,展望未来发展方向和应用前景.
Research progress of pan-immune inflammation value in prognosis and effect of tumors
Pan-immune inflammation value(PIV)is a comprehensive immune inflammatory bio-marker based on complete blood cell counts,which has been proven to predict treatment response and survival outcomes for different types of tumors.However,the predictive value of the PIV varies in dif-ferent strategies for tumor treatment.This paper aims to systematically review the latest progress of PIV in predicting survival outcomes and tumor prognosis for immunotherapy,radiotherapy,targeted therapy,endocrine therapy,surgical treatment and neoadjuvant therapy,and analyze its existing challenges and issues,as well as look forward to its future development direction and application prospects.

tumorspan-immune inflammation valuepredictionprognosisefficacybiomarkers

李添翼、任粤、宋震亚、江美南、李梦扬、陈勇、殷旭东

展开 >

扬州大学附属医院肿瘤科,江苏扬州,225000

肿瘤 泛免疫炎症指数 预测 预后 疗效 生物标志物

江苏省自然科学基金资助项目江苏省产学研合作项目

BK20191218BY20221106

2024

实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
年,卷(期):2024.28(5)
  • 46